We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+33.16%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$745M
AUM Growth
+$34.8M
Cap. Flow
-$59.1M
Cap. Flow %
-7.93%
Top 10 Hldgs %
91.04%
Holding
31
New
2
Increased
8
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
LCI
Lannett Company, Inc.
LCI
+$54M
2
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$51.2M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$4.12M
4
OSIR
Osiris Therapeutics, Inc. Common Stock
OSIR
+$2.78M
5
OFIX icon
Orthofix Medical
OFIX
+$2.35M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$38.5M
2
CSII
Cardiovascular Systems, Inc.
CSII
+$36.9M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$20.6M
4
INSY
Insys Therapeutics, Inc.
INSY
+$19.1M
5
EPRS
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 90.18%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$125M 16.73%
1,406,137
+52,224
+4% +$4.12M
INSY
2
DELISTED
Insys Therapeutics, Inc.
INSY
$73.5M 9.86%
2,568,684
-688,410
-21% -$19.1M
OFIX icon
3
Orthofix Medical
OFIX
$455M
$72.5M 9.73%
1,849,396
+62,861
+4% +$2.35M
PACB icon
4
Pacific Biosciences
PACB
$422M
$72.2M 9.68%
5,498,712
-759,149
-12% -$6.81M
AKRX
5
DELISTED
Akorn Inc
AKRX
$70.7M 9.48%
1,893,756
+20,000
+1% +$625K
TVTX icon
6
Travere Therapeutics
TVTX
$5.33B
$66.8M 8.95%
3,460,323
+10,000
+0.3% +$200K
MNK
7
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$56.7M 7.61%
+760,000
New +$51.2M
LCI
8
DELISTED
Lannett Company, Inc.
LCI
$52.8M 7.09%
+329,175
New +$54M
ABBV icon
9
AbbVie
ABBV
$458B
$46.1M 6.18%
778,000
-667,900
-46% -$38.5M
ANIP icon
10
ANI Pharmaceuticals
ANIP
$1.77B
$42.7M 5.73%
946,489
-109,800
-10% -$4.73M
OSIR
11
DELISTED
Osiris Therapeutics, Inc. Common Stock
OSIR
$23.3M 3.12%
2,240,709
+205,000
+10% +$2.78M
VNDA icon
12
Vanda Pharmaceuticals
VNDA
$312M
$10.2M 1.37%
1,093,696
-343,100
-24% -$3.42M
ADMA icon
13
ADMA Biologics
ADMA
$1.92B
$8.55M 1.15%
1,060,017
+7,875
+0.7% +$70.9K
CPRX
14
DELISTED
Catalyst Pharmaceutical
CPRX
$7.08M 0.95%
2,888,942
-2,913,943
-50% -$8.35M
VCEL icon
15
Vericel Corp
VCEL
$2.3B
$6.07M 0.81%
2,352,940
– –
DSCI
16
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$4.28M 0.57%
937,516
-955,951
-50% -$4.53M
SPNE
17
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$2.54M 0.34%
147,723
-100,779
-41% -$1.59M
AXGN icon
18
Axogen
AXGN
$2.1B
$2.03M 0.27%
406,351
+181,951
+81% +$899K
VCYT icon
19
Veracyte
VCYT
$4.52B
$1.19M 0.16%
165,825
-100,969
-38% -$680K
BIOL
20
DELISTED
Biolase, Inc.
BIOL
$922K 0.12%
88
-4
-4% -$43.7K
CTIC
21
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$635K 0.09%
51,000
+5,000
+11% +$66.8K
MSLI
22
DELISTED
Merus Labs International Inc.
MSLI
$47K 0.01%
28,484
-1,275,000
-98% -$1.74M
ENTA icon
23
Enanta Pharmaceuticals
ENTA
$372M
– –
-570,662
Closed -$20.6M
LCTX icon
24
Lineage Cell Therapeutics
LCTX
$257M
– –
-668,620
Closed -$1.62M
SIEN
25
DELISTED
Sientra, Inc.
SIEN
– –
-5,966
Closed -$606K
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2015 Portfolio in Review

As of Q4 2015, Consonance Capital Management held 31 positions worth $745M, up 4.9% from $711M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Consonance Capital Management withdrew a net $59.1M in Q4 2015, closing 9 positions and reducing 11 holdings. Its most notable exit was Cardiovascular Systems, Inc., an estimated $36.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 85% a quarter earlier, followed by Technology.

Against the trend, Consonance Capital Management opened a new position in Lannett Company, Inc. worth $52.8M.

  • Consonance Capital Management's largest Q4 2015 buy was Lannett Company, Inc.: 329,175 shares worth $52.8M.
  • Consonance Capital Management added most to Eagle Pharmaceuticals, Inc. in Q4 2015, an estimated $4.12M increase.
  • Consonance Capital Management's biggest Q4 2015 reduction was AbbVie, cutting an estimated $38.5M.
  • Consonance Capital Management fully exited Cardiovascular Systems, Inc. in Q4 2015, selling an estimated $36.9M.
  • Consonance Capital Management's ten largest holdings make up 91% of its $745M portfolio in Q4 2015.
  • Consonance Capital Management opened 2 new positions and closed 9 in Q4 2015.
  • Consonance Capital Management's portfolio value rose 4.9% quarter-over-quarter to $745M.

Based on Consonance Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.